newsfilter
← Latest News
Business Wire·

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage